ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.110
-0.240 (-10.21%)
At close: Feb 27, 2026, 4:00 PM EST
2.030
-0.080 (-3.79%)
After-hours: Feb 27, 2026, 7:25 PM EST
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
276.83M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| Fennec Pharmaceuticals | 38.79M |
| Alector | 21.05M |
| Opus Genetics | 14.63M |
| AC Immune | 5.48M |
| Abeona Therapeutics | 400.00K |
| Inhibikase Therapeutics | 1.00 |
| Adlai Nortye | -1.35M |
ALXO News
- 1 day ago - ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 - GlobeNewsWire
- 9 days ago - ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 - GlobeNewsWire
- 4 weeks ago - ALX Oncology Announces Pricing of Underwritten Offering - GlobeNewsWire
- 4 weeks ago - New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - GlobeNewsWire
- 6 weeks ago - ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire